Ophthalmology · Antimalarial Drug-Induced Toxic Maculopathy

Recognizing the Warning Signs of Retinal Damage

At a Glance

Antimalarial retinal damage can begin without symptoms and may occur despite 20/20 vision, so scheduled eye screening matters. Reading problems, blind spots, faded colors, or central vision loss need prompt eye care, while sudden changes require same-day emergency assessment.

One of the most dangerous aspects of antimalarial retinopathy is how quiet it is in the beginning. Because the damage often starts in a ring around your central vision, rather than directly in the middle, you may have “perfect” 20/20 vision on a standard eye chart while the medication is actively causing abnormalities in your retina ^[1]^[2].

While symptoms often indicate that the disease has reached a later stage, seeking prompt care when you notice them is still critical to preserving your remaining vision. However, waiting for symptoms to appear before getting checked defeats the purpose of screening ^[3]^[4].

The “Silent” Early Phase

In the early stages, toxicity is frequently asymptomatic, meaning you feel and see nothing unusual. Your eyes look normal in a mirror, and you can still read, drive, and see colors clearly.

Advanced medical scans like OCT (Optical Coherence Tomography) can see microscopic thinning of the retinal layers long before you experience any vision loss ^[5]^[6]. If the medication is stopped during this silent phase, your vision can often be saved ^[6]^[7].

Symptoms of Advanced Progression

As the damage moves from the “silent” early phase into more established stages, you may begin to notice specific functional changes. These symptoms are nonspecific and can also be caused by other eye conditions, but they often develop slowly over months or years:

Reading Difficulties: You might find that letters or whole words seem to “jump” or disappear while you are reading, even if you are wearing the correct glasses ^[8]^[9].
Paracentral Scotomas: These are small scotomas (blind spots) that sit just off to the side of where you are looking. You may notice “flickering” or gray patches in your vision that don’t go away ^[10]^[11].
Reduced Color Vision: Colors may appear less vibrant or “washed out,” particularly reds ^[3]^[12].
Central Vision Loss: In the late stages, the damage may move into the very center of the eye (the fovea), leading to a significant loss of detail and clarity ^[7]^[6].

Red Flags: When to Seek Immediate Care

Antimalarial toxicity typically progresses very slowly. If you experience rapid or sudden vision changes, it may indicate a completely different and critical eye emergency, such as a retinal detachment or a vascular occlusion ^[13]^[14].

Do NOT wait 24-48 hours. Seek SAME-DAY emergency medical care (go to an emergency room or contact an on-call ophthalmologist immediately) if you experience:

A New “Curtain” or Shadow: A dark shadow or curtain moving across your field of vision.
Sudden Vision Loss: Any significant, painless loss of vision in one or both eyes ^[13].
Sudden Flashes or Floaters: A sudden burst of light flashes or a swarm of new floaters.
Sudden Bilateral Blurring: A rapid, severe loss of clarity in both eyes over a few days ^[15].

Clarifying Systemic Symptoms

It is common for patients taking these medications to have “flares” of their underlying condition. While joint pain, new skin rashes, fatigue, and mild headaches are not typical signs of retinal toxicity, they can be signs of a serious systemic flare ^[16]^[17]. Furthermore, severe systemic symptoms—like sudden shortness of breath, chest pain, or neurologic changes—are medical emergencies and require immediate assessment by your general medical team ^[18]. Do not ignore them just because they aren’t related to your eyes.

Common questions in this guide

Can antimalarial retinal damage start without symptoms?

Yes. Early retinal toxicity is often silent, and you may still read, drive, see colors, and score 20/20 on a standard eye chart. Normal vision does not replace scheduled screening.

What vision changes can be warning signs of antimalarial retinopathy?

Slowly developing trouble reading, missing letters or words, flickering or gray blind spots beside the center of vision, faded colors—especially red—and later loss of central detail can be warning signs. These changes can have other causes, so an ophthalmologist should evaluate them promptly.

When should I seek emergency care for vision changes while taking an antimalarial?

Seek same-day emergency care for a new curtain or shadow, sudden significant vision loss, sudden flashes or many new floaters, or rapid severe blurring in both eyes. These symptoms can signal emergencies such as retinal detachment or a blocked blood vessel rather than the usual slow course of antimalarial toxicity.

How can eye doctors find antimalarial retinal damage before symptoms?

OCT imaging can show microscopic thinning of retinal layers before you notice vision loss. Your ophthalmologist may also use visual-field testing, such as a 10-2 or 30-2 test, based on your clinical risk factors and screening plan.

Are joint pain, a rash, fatigue, or a mild headache signs of antimalarial retinal toxicity?

They are not typical signs of retinal toxicity, but they may indicate a flare of the condition being treated. Severe shortness of breath, chest pain, or new neurologic changes need immediate assessment by your medical team.

Get notified when new evidence is published on Toxic maculopathy due to antimalarial drugs.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Optical Coherence Tomography and Angiography in Hydroxychloroquine Retinopathy: A Narrative Review.
Donica AL, Donica VC, Russu M, et al.
Diagnostics (Basel, Switzerland) 2026; (16(3)) doi:10.3390/diagnostics16030463.
PMID: 41681781
2
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung LS, Neal JW, Wakelee HA, et al.
American journal of ophthalmology 2015; (160(4)):799-805.e1.
PMID: 26189086
3
The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom.
Yusuf IH, Han RC, Downes SM, Sharma SM
Eye (London, England) 2024; (38(14)):2796-2804 doi:10.1038/s41433-024-03168-0.
PMID: 39085597
4
Unmet needs and future perspectives in hydroxychloroquine retinopathy.
Yusuf IH, Charbel Issa P, Ahn SJ
Frontiers in medicine 2023; (10()):1196815 doi:10.3389/fmed.2023.1196815.
PMID: 37359010
5
New proposal for a multimodal imaging approach for the subclinical detection of hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus.
Araújo O, Casaroli-Marano RP, Hernández-Rodríguez J, et al.
BMJ open ophthalmology 2024; (9(1)) doi:10.1136/bmjophth-2023-001608.
PMID: 38499344
6
LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.
Allahdina AM, Chen KG, Alvarez JA, et al.
Retina (Philadelphia, Pa.) 2019; (39(3)):473-484 doi:10.1097/IAE.0000000000002437.
PMID: 30741731
7
Long-Term Progression of Pericentral Hydroxychloroquine Retinopathy.
Ahn SJ, Seo EJ, Kim KE, et al.
Ophthalmology 2021; (128(6)):889-898 doi:10.1016/j.ophtha.2020.10.029.
PMID: 33129843
8
Case Report: Hydroxychloroquine Retinopathy.
Eldeeb M, Chan EW, Omar A
Optometry and vision science : official publication of the American Academy of Optometry 2018; (95(6)):545-549 doi:10.1097/OPX.0000000000001226.
PMID: 29787487
9
Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
Manoj M, Sahoo RR, Singh A, et al.
Rheumatology international 2021; (41(5)):929-937 doi:10.1007/s00296-021-04831-5.
PMID: 33704526
10
Visual field examinations using different strategies in Asian patients taking hydroxychloroquine.
Kim KE, Ryu SJ, Kim YH, et al.
Scientific reports 2022; (12(1)):14778 doi:10.1038/s41598-022-19048-0.
PMID: 36042337
11
Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy.
Browning DJ, Lee C
Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):943-52 doi:10.2147/OPTH.S82398.
PMID: 26060390
12
Dermatologists' and Rheumatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: A Cross-Sectional Study.
Alghamdi AS, AlQefari GB, Alduraibi K, et al.
Cureus 2024; (16(3)):e56179 doi:10.7759/cureus.56179.
PMID: 38618426
13
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Ameen Ismail A, Sadek SH, Hatata RM
BMC ophthalmology 2022; (22(1)):434 doi:10.1186/s12886-022-02657-8.
PMID: 36376841
14
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Delavar A, Baxter SL
BMJ case reports 2022; (15(11)) doi:10.1136/bcr-2022-249509.
PMID: 36384882
15
Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.
Wang G, Zhuo N, Liao Z, et al.
Medicine 2021; (100(22)):e25688 doi:10.1097/MD.0000000000025688.
PMID: 34087822
16
Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R, Bornkamp N, Kim MY, et al.
Arthritis research & therapy 2020; (22(1)):191 doi:10.1186/s13075-020-02282-0.
PMID: 32807233
17
Risk of flare in patients with SLE in remission after hydroxychloroquine or chloroquine withdrawal.
Trefond L, Mathian A, Lhote R, et al.
Joint bone spine 2024; (91(6)):105756 doi:10.1016/j.jbspin.2024.105756.
PMID: 38964624
18
Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
Ichikawa K, Kirino Y, Kunishita Y, et al.
Modern rheumatology case reports 2021; (5(2)):259-264 doi:10.1080/24725625.2021.1881215.
PMID: 33533686

This page explains warning signs and screening for antimalarial retinal toxicity for informational purposes only and does not constitute medical advice. Contact an ophthalmologist promptly for new vision changes, and seek same-day emergency care for sudden changes.